Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794503 · ClinicalTrials.gov registry record · Phase 4
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 235
- Enrollment target
NCT05794503 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 235 participants.
The verdict
NCT05794503, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 235 participants
- Enrollment target
Study Summary
This study is intended to be a single-site, prospective, randomized, controlled study that intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of rocuronium-induced neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. To account for protocol deviations and patient dropout, up to 250 randomization envelopes will be made and enrollment will continue until there are 230 completed enrollments.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05794503
The ClinicalTrials.gov registry entry for NCT05794503 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT05794503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05794503 about?
NCT05794503 is a clinical study titled "Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex". This study is intended to be a single-site, prospective, randomized, controlled study that intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of rocuronium-induce...
What is the current status of trial NCT05794503?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 235 participants. The study started on 2023-09-11. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT05794503?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT05794503?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.